Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
A 25-year-old woman with androgenic alopecia is experiencing hair dryness and damage after using topical minoxidil and Nizoral. She is advised to reduce washing frequency, use a bond builder like K18, apply a silicone-based serum, and consider using a shower filter and different oils like argan oil for better hair health.
The user shared 9-month results using a 4-in-1 spray containing finasteride, minoxidil, ketoconazole, and biotin, along with lifestyle changes like jogging, quitting smoking, and using collagen supplements. They also incorporated dermastamping, dermarolling, and various oils into their routine, reporting positive hair regrowth.
Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.
A user reports hair regrowth after 8 months using treatments including topical Minoxidil/Finasteride, microneedling, Nizoral shampoo, Pyrilutamide, GHK-Cu/Min topical, and supplements like fish collagen peptides, zinc, and vitamin D3. They've seen progress but slower regrowth in the midsection of the scalp and are seeking advice to improve it.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.